UA107954C2 - Substituted pyrrolidin-2-carboxamide - Google Patents
Substituted pyrrolidin-2-carboxamideInfo
- Publication number
- UA107954C2 UA107954C2 UAA201210421A UAA201210421A UA107954C2 UA 107954 C2 UA107954 C2 UA 107954C2 UA A201210421 A UAA201210421 A UA A201210421A UA A201210421 A UAA201210421 A UA A201210421A UA 107954 C2 UA107954 C2 UA 107954C2
- Authority
- UA
- Ukraine
- Prior art keywords
- carboxamide
- substituted pyrrolidin
- compounds
- pyrrolidin
- substituted
- Prior art date
Links
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical class NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/702,402 US8354444B2 (en) | 2008-09-18 | 2010-02-09 | Substituted pyrrolidine-2-carboxamides |
| PCT/EP2011/051619 WO2011098398A1 (en) | 2010-02-09 | 2011-02-04 | Substituted pyrrolidine-2-carboxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA107954C2 true UA107954C2 (en) | 2015-03-10 |
Family
ID=43608850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201210421A UA107954C2 (en) | 2010-02-09 | 2011-04-02 | Substituted pyrrolidin-2-carboxamide |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8354444B2 (ru) |
| EP (1) | EP2534132B1 (ru) |
| JP (1) | JP5612710B2 (ru) |
| KR (1) | KR101461298B1 (ru) |
| CN (1) | CN102753522B (ru) |
| AR (2) | AR080143A1 (ru) |
| AU (1) | AU2011214506C1 (ru) |
| BR (1) | BR112012019672B1 (ru) |
| CA (1) | CA2788236C (ru) |
| CL (1) | CL2012002189A1 (ru) |
| CR (1) | CR20120410A (ru) |
| CY (1) | CY1119049T1 (ru) |
| DK (1) | DK2534132T3 (ru) |
| EC (1) | ECSP12012083A (ru) |
| ES (1) | ES2629439T3 (ru) |
| HK (1) | HK1171452A1 (ru) |
| HR (1) | HRP20170903T1 (ru) |
| HU (1) | HUE034816T2 (ru) |
| LT (1) | LT2534132T (ru) |
| MX (1) | MX2012009186A (ru) |
| MY (1) | MY165238A (ru) |
| NZ (1) | NZ601422A (ru) |
| PE (1) | PE20121532A1 (ru) |
| PL (1) | PL2534132T3 (ru) |
| PT (1) | PT2534132T (ru) |
| RS (1) | RS56163B1 (ru) |
| RU (1) | RU2564022C2 (ru) |
| SG (1) | SG182763A1 (ru) |
| SI (1) | SI2534132T1 (ru) |
| TW (1) | TWI401243B (ru) |
| UA (1) | UA107954C2 (ru) |
| WO (1) | WO2011098398A1 (ru) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7303676B2 (en) * | 2003-02-13 | 2007-12-04 | Zenon Technology Partnership | Supported biofilm apparatus and process |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US8859776B2 (en) | 2009-10-14 | 2014-10-14 | Merck Sharp & Dohme Corp. | Substituted piperidines that increase p53 activity and the uses thereof |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| JP5792279B2 (ja) | 2011-03-10 | 2015-10-07 | 第一三共株式会社 | ジスピロピロリジン誘導体 |
| EP2771008A4 (en) | 2011-10-28 | 2015-04-08 | Merck Sharp & Dohme | MACROCYCLES INCREASING P53 ACTIVITY AND USES THEREOF |
| EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20140200255A1 (en) * | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
| US20130245089A1 (en) * | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| RU2014150492A (ru) | 2012-05-30 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| BR112015015758B1 (pt) * | 2013-01-22 | 2022-01-04 | F. Hoffmann-La Roche Ag | Dispersão sólida, formulação sólida de dose unitária, preparação farmacêutica e uso de uma dispersão sólida |
| US9828340B2 (en) * | 2013-02-21 | 2017-11-28 | Hoffmann-La Roche Inc. | Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide |
| US20140275562A1 (en) * | 2013-03-13 | 2014-09-18 | Dow Agrosciences Llc | Preparation of certain (substituted phenyl)-triazolyl-(substituted phenyl) molecules, and intermediates and insecticides related thereto |
| BR112015030734A2 (pt) * | 2013-06-19 | 2017-07-25 | Hoffmann La Roche | produto farmacêutico, kit e método de tratamento |
| US20160129033A1 (en) * | 2013-06-19 | 2016-05-12 | Hoffmann-La Roche Inc. | Combination of ro5503781 and capecitabine for cancer therapy |
| WO2014206866A1 (en) * | 2013-06-24 | 2014-12-31 | F. Hoffmann-La Roche Ag | Stable intravenous formulation |
| KR101879926B1 (ko) | 2013-07-03 | 2018-08-16 | 에프. 호프만-라 로슈 아게 | MDM2 길항제를 사용한 환자 암 치료를 개인화하기 위한 mRNA-기반 유전자 발현 |
| SI3077004T1 (sl) | 2013-12-05 | 2020-07-31 | F. Hoffmann-La Roche Ag | Novo kombinirano zdravilo za akutno mieloično levkemijo (AML) |
| US9657351B2 (en) | 2013-12-06 | 2017-05-23 | Hoffman-La Roche Inc. | MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist |
| EP3131878A1 (en) * | 2014-04-15 | 2017-02-22 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
| ES2712973T3 (es) | 2014-04-17 | 2019-05-17 | Univ Michigan Regents | Inhibidores de MDM2 y métodos terapéuticos que usan los mismos |
| JP6162646B2 (ja) * | 2014-05-27 | 2017-07-12 | 信越化学工業株式会社 | ３，５−ジメチルドデカン酸の製造方法 |
| WO2016055497A1 (en) * | 2014-10-10 | 2016-04-14 | F. Hoffmann-La Roche Ag | Methods for personalizing patient cancer therapy with an mdm2 antagonist |
| SG11201706542TA (en) * | 2015-03-30 | 2017-10-30 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| KR102122469B1 (ko) | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
| CA3048088C (en) | 2016-12-30 | 2021-05-04 | Oriental (Luzhou) Agrochemicals. Co., Ltd. | Method for preparing 2-(cyclohexenylidene) malonic acid derivatives and uses thereof |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| CN108586195A (zh) * | 2017-12-27 | 2018-09-28 | 北京汇康博源医药科技有限公司 | 一种5-羟基-7，7-二甲基-2h-茚酮的制备方法 |
| WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
| KR20220124176A (ko) | 2019-12-06 | 2022-09-13 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 치환된 테트라하이드로푸란 |
| KR20240031300A (ko) | 2021-06-04 | 2024-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널 조절제로서의 n-(하이드록시알킬 (헤테로)아릴) 테트라하이드로푸란 카르복스아미드 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN116459225B (zh) * | 2023-04-26 | 2023-11-10 | 东莞市金美济药业有限公司 | 一种艾拉戈克钠片及其制备工艺 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732902A (en) | 1986-05-23 | 1988-03-22 | Hoffmann-La Roche Inc. | Pyrroloisoquinolinyl-dimethyloxoalkyl alkonoates and their use as antipsychotic agents |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| CA2298601A1 (en) | 1997-08-28 | 1999-03-11 | Pharmacia & Upjohn Company | Inhibitors of protein tyrosine phosphatase |
| US6482921B1 (en) | 1999-01-28 | 2002-11-19 | Essential Therapeutics, Inc. | Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use |
| US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| CN1294120C (zh) * | 2003-10-21 | 2007-01-10 | 山东大学 | 吡咯烷类基质金属蛋白酶抑制剂及其应用 |
| US7550487B2 (en) * | 2004-03-26 | 2009-06-23 | Hoffmann-La Roche Inc. | Pyrrolidine-3,4-dicarboxamide derivatives |
| SG176463A1 (en) * | 2005-02-22 | 2011-12-29 | Univ Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| EA014445B1 (ru) | 2005-02-22 | 2010-12-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 и их применения |
| CN101243069A (zh) | 2005-06-17 | 2008-08-13 | 阿斯利康(瑞典)有限公司 | 凝血酶抑制剂2-氧代-1,2,5,6-四氢吡啶衍生物 |
| US7884107B2 (en) | 2006-06-30 | 2011-02-08 | Merck | Substituted piperidines that increase P53 activity and the uses thereof |
| RU2459619C2 (ru) | 2006-12-06 | 2012-08-27 | Санофи-Авентис | Мочевина и сульфамидные производные в качестве ингибиторов tafia |
| TW200911787A (en) | 2007-07-03 | 2009-03-16 | Astrazeneca Ab | New aza-bicyclohexane compounds useful as inhibitors of thrombin |
| JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
| US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| KR101673886B1 (ko) | 2008-06-06 | 2016-11-08 | 사노피 | ＴＡＦＩａ의 억제제로서의 마크로사이클릭 우레아 및 술파미드 유도체 |
| EP2321301A4 (en) | 2008-06-23 | 2011-09-28 | Astrazeneca Ab | NOVEL HETEROCYCLIC CARBOXAMIDES AS THROMBIN INHIBITORS |
| GB0811643D0 (en) * | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| JP5658157B2 (ja) | 2008-09-18 | 2015-01-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換ピロリジン−２−カルボキサミド |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
-
2010
- 2010-02-09 US US12/702,402 patent/US8354444B2/en active Active
-
2011
- 2011-02-04 PE PE2012001184A patent/PE20121532A1/es active IP Right Grant
- 2011-02-04 LT LTEP11702449.7T patent/LT2534132T/lt unknown
- 2011-02-04 MX MX2012009186A patent/MX2012009186A/es active IP Right Grant
- 2011-02-04 MY MYPI2012003543A patent/MY165238A/en unknown
- 2011-02-04 CN CN2011800089274A patent/CN102753522B/zh active Active
- 2011-02-04 JP JP2012552343A patent/JP5612710B2/ja active Active
- 2011-02-04 HU HUE11702449A patent/HUE034816T2/en unknown
- 2011-02-04 SI SI201131222T patent/SI2534132T1/sl unknown
- 2011-02-04 BR BR112012019672-3A patent/BR112012019672B1/pt active IP Right Grant
- 2011-02-04 RS RS20170658A patent/RS56163B1/sr unknown
- 2011-02-04 AU AU2011214506A patent/AU2011214506C1/en active Active
- 2011-02-04 ES ES11702449.7T patent/ES2629439T3/es active Active
- 2011-02-04 RU RU2012138257/04A patent/RU2564022C2/ru active
- 2011-02-04 PL PL11702449T patent/PL2534132T3/pl unknown
- 2011-02-04 PT PT117024497T patent/PT2534132T/pt unknown
- 2011-02-04 DK DK11702449.7T patent/DK2534132T3/en active
- 2011-02-04 NZ NZ601422A patent/NZ601422A/en unknown
- 2011-02-04 KR KR1020127023297A patent/KR101461298B1/ko active IP Right Grant
- 2011-02-04 SG SG2012055752A patent/SG182763A1/en unknown
- 2011-02-04 CA CA2788236A patent/CA2788236C/en active Active
- 2011-02-04 WO PCT/EP2011/051619 patent/WO2011098398A1/en active Application Filing
- 2011-02-04 EP EP11702449.7A patent/EP2534132B1/en active Active
- 2011-02-07 AR ARP110100393A patent/AR080143A1/es active IP Right Grant
- 2011-02-08 TW TW100104166A patent/TWI401243B/zh active
- 2011-04-02 UA UAA201210421A patent/UA107954C2/ru unknown
-
2012
- 2012-08-03 EC ECSP12012083 patent/ECSP12012083A/es unknown
- 2012-08-07 CL CL2012002189A patent/CL2012002189A1/es unknown
- 2012-08-07 CR CR20120410A patent/CR20120410A/es unknown
- 2012-11-29 HK HK12112287.3A patent/HK1171452A1/xx unknown
-
2017
- 2017-06-13 HR HRP20170903TT patent/HRP20170903T1/hr unknown
- 2017-06-23 CY CY20171100673T patent/CY1119049T1/el unknown
-
2018
- 2018-12-13 AR ARP180103640A patent/AR114159A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA107954C2 (en) | Substituted pyrrolidin-2-carboxamide | |
| MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| IN2014MN02657A (ru) | ||
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| EA201590534A1 (ru) | Новые бициклические производные | |
| IN2014MN02652A (ru) | ||
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| IN2014MN02598A (ru) | ||
| CR20140106A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| IN2014MN02658A (ru) | ||
| EA201401054A1 (ru) | N-циклиламиды в качестве нематоцидов | |
| CR20130539A (es) | Triazolopiridinas | |
| CO6361910A2 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| IN2015DN00598A (ru) | ||
| EA201590321A1 (ru) | Дейтерированный барицитиниб | |
| EA201490919A1 (ru) | Производные бетулина | |
| UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
| IN2012DN02487A (ru) | ||
| MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
| MX345780B (es) | Inhibidores triciclicos de girasa. | |
| IN2015DN01119A (ru) | ||
| IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
| UA111744C2 (uk) | ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk | |
| EA201591024A1 (ru) | Димерные соединения |